Intellectual Property
Leveraging a Novel Drug Discovery Platform
Helus Pharma is engineering novel serotonergic agonists (NSAs) and next-generation molecules by modifying serotonin receptor agonist scaffolds, resulting in proprietary active pharmaceutical ingredients (APIs).
Our pipeline portfolio of differentiated, proprietary NSA drug candidates includes over 350 filed patents with more than 100 already granted.
Our molecules are designed for improved safety, bioavailability, pharmacokinetics, and controlled delivery, with the goal of fully unlocking and optimizing their therapeutic potential for patients and clinicians.
This approach has been integral to the discovery and development of our lead clinical-stage assets, HLP003, our proprietary deuterated NSA program in development for the treatment of Major Depressive Disorder, and HLP004, our deuterated NSA program in development for the treatment of Generalized Anxiety Disorder.
Advancing Innovative Deuterated Novel Serotonergic Agonists
Helus Pharma pairs its novel serotonergic agonists with deuteration technology, designed to enable:
- Fast onset of action
- Improved dosing control
- Short treatment duration
- Consistent and predictable responses
- Less invasive, patient-friendly dosing methods
Our proprietary drug optimization technologies are broadly applicable across multiple compounds, including both deuterated and non-deuterated novel serotonergic agonists, pioneering a paradigm shift in mental health therapeutics.